- Previous Close
12.96 - Open
12.96 - Bid 12.94 x 200
- Ask 13.02 x 100
- Day's Range
12.75 - 13.82 - 52 Week Range
6.99 - 17.75 - Volume
1,597,709 - Avg. Volume
2,509,972 - Market Cap (intraday)
1.543B - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.16 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
www.arcutis.comRecent News: ARQT
View More
Performance Overview: ARQT
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARQT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARQT
View MoreValuation Measures
Market Cap
1.54B
Enterprise Value
1.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.01
Price/Book (mrq)
9.80
Enterprise Value/Revenue
7.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-71.25%
Return on Assets (ttm)
-23.25%
Return on Equity (ttm)
-113.76%
Revenue (ttm)
196.54M
Net Income Avi to Common (ttm)
-140.04M
Diluted EPS (ttm)
-1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
227.96M
Total Debt/Equity (mrq)
70.19%
Levered Free Cash Flow (ttm)
-73.08M
Research Analysis: ARQT
View MoreResearch Reports: ARQT
View MoreDaily – Vickers Top Buyers & Sellers for 12/04/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/27/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.